SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus
Author:
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Reference28 articles.
1. Recent and emerging anti-diabetes targets;Mohler;Med Res Rev,2009
2. Current therapies and emerging targets for the treatment of diabetes;Wagman;Curr Pharm Des,2001
3. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice;Katsuno;Eur J Pharmacol,2009
4. Thiazolidinediones, insulin resistance and obesity: finding a balance;Wilding;Int J Clin Pract,2006
5. Emerging therapies for metabolic diseases: the focus is on diabetes and obesity;Hughes;Curr Opin Chem Biol,2009
Cited by 68 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Diverse Clinical Effects of SGLT2 Inhibitor: Case Presentation and Literature Mini-review;Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences);2023-09-10
2. Postcardiac Surgery Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Cotransporter 2 Inhibitors;Journal of Cardiothoracic and Vascular Anesthesia;2023-06
3. Sodium glucose co-transporter 2 inhibition with empagliflozin on metabolic, cardiac and renal outcomes in recent cardiac transplant recipients (EMPA-HTx): protocol for a randomised controlled trial;BMJ Open;2023-03
4. Structure-related relationship: Plant-derived antidiabetic compounds;Studies in Natural Products Chemistry;2023
5. A Network Pharmacology to Explore the Potential Targets of Canagliflozin and Dapagliflozin in Treating Atherosclerosis;Journal of Vascular Diseases;2022-09-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3